doi: 10.3324/haematol.10327.
FCgammaRIIIA and FCgammaRIIA polymorphisms are not associated with response to rituximab and CHOP in patients with diffuse large B-cell lymphoma
Affiliations
- PMID: 17606457
- DOI: 10.3324/haematol.10327
Item in Clipboard
FCgammaRIIIA and FCgammaRIIA polymorphisms are not associated with response to rituximab and CHOP in patients with diffuse large B-cell lymphoma
Haematologica.
2007 Jul.
Free article
Abstract
We investigated the association ofFcgammaRIIIaa and FcgRIIa polymorphisms and response to R-CHOP in 58 patients with diffuse large B-cell lymphoma (DLBCL). FcgammaRIIIa and FcgRIIa polymorphisms did not influence response, event-free or overall survival. These results suggest that ADCC via FcgammaRIIIa and FcgammaRIIa may not be the major mechanism of activity of the R-CHOP combination in DLBCL.
Similar articles
-
[Diffuse large B-cell lymphoma: standard treatment and research questions].Rinsho Ketsueki. 2019;60(9):1193-1198. doi: 10.11406/rinketsu.60.1193. Rinsho Ketsueki. 2019. PMID: 31597843 Review. Japanese.
-
How gene polymorphisms can influence clinical response and toxicity following R-CHOP therapy in patients with diffuse large B cell lymphoma.Blood Rev. 2017 Jul;31(4):235-249. doi: 10.1016/j.blre.2017.02.005. Epub 2017 Feb 27. Blood Rev. 2017. PMID: 28262268 Review.
-
FcγRIIA and FcγRIIIA polymorphisms do not influence survival and response to rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone immunochemotherapy in patients with diffuse large B-cell lymphoma.Leuk Lymphoma. 2011 Aug;52(8):1604-6. doi: 10.3109/10428194.2011.574760. Epub 2011 Jun 10. Leuk Lymphoma. 2011. PMID: 21657954 No abstract available.
-
CHOP-R therapy overcomes the adverse prognostic influence of BCL-2 expression in diffuse large B-cell lymphoma.Leuk Lymphoma. 2007 Jun;48(6):1102-9. doi: 10.1080/10428190701344881. Leuk Lymphoma. 2007. PMID: 17577773
-
FCGR3A gene polymorphisms may correlate with response to frontline R-CHOP therapy for diffuse large B-cell lymphoma.Blood. 2006 Oct 15;108(8):2720-5. doi: 10.1182/blood-2006-01-009480. Epub 2006 Apr 11. Blood. 2006. PMID: 16609067 Clinical Trial.
Cited by
-
Relevance of Fc Gamma Receptor Polymorphisms in Cancer Therapy With Monoclonal Antibodies.Front Oncol. 2022 Jun 24;12:926289. doi: 10.3389/fonc.2022.926289. eCollection 2022. Front Oncol. 2022. PMID: 35814459 Free PMC article. Review.
-
Role of the ITAM-Bearing Receptors Expressed by Natural Killer Cells in Cancer.Front Immunol. 2022 Jun 10;13:898745. doi: 10.3389/fimmu.2022.898745. eCollection 2022. Front Immunol. 2022. PMID: 35757695 Free PMC article. Review.
-
Molecular Aspects of Resistance to Immunotherapies-Advances in Understanding and Management of Diffuse Large B-Cell Lymphoma.Int J Mol Sci. 2022 Jan 28;23(3):1501. doi: 10.3390/ijms23031501. Int J Mol Sci. 2022. PMID: 35163421 Free PMC article. Review.
-
Single-nucleotide Fcγ receptor polymorphisms do not impact obinutuzumab/rituximab outcome in patients with lymphoma.Blood Adv. 2021 Aug 10;5(15):2935-2944. doi: 10.1182/bloodadvances.2020003985. Blood Adv. 2021. PMID: 34323957 Free PMC article.
-
Harnessing CD16-Mediated NK Cell Functions to Enhance Therapeutic Efficacy of Tumor-Targeting mAbs.Cancers (Basel). 2021 May 20;13(10):2500. doi: 10.3390/cancers13102500. Cancers (Basel). 2021. PMID: 34065399 Free PMC article. Review.
Publication types
MeSH terms
Substances
Supplementary concepts
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
